Remdesivir does not improve Covid-19 survival odds, a large World Health Organisation (WHO) trial of it and three other treatments has ruled.
More than 11,200 hospitalised Covid-19 patients around the world were treated with remdesivir - an antiviral - lopinavir, hydroxychloroquine, interferon or a placebo for the WHO's massive SOLIDARITY trial.
None of the drugs "substantially affected" mortality risks, the dismal report found.
It's a blow to hopes that the world is getting better at treating people affected in the pandemic that has claimed the lives of more than a million people globally, including more than 217,000 in the US.